BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 14501979)

  • 1. Advances in positive inotropic therapy: levosimendan.
    Frishman WH
    Crit Care Med; 2003 Sep; 31(9):2408-9. PubMed ID: 14501979
    [No Abstract]   [Full Text] [Related]  

  • 2. Patients with advanced heart failure and the effects of levosimendan.
    Song ZZ; Ma J
    Am J Cardiol; 2007 Aug; 100(4):742; author reply 742-3. PubMed ID: 17697841
    [No Abstract]   [Full Text] [Related]  

  • 3. Levosimendan: perpetuum mobile?
    Agewall S; Atar D
    Eur Heart J; 2007 Feb; 28(4):515. PubMed ID: 17283001
    [No Abstract]   [Full Text] [Related]  

  • 4. [Acute hemodynamic and clinical effects of a new inotropic agent, levosimendan, in patients with severe heart failure].
    Porcu M; OrrĂ¹ P
    Ital Heart J Suppl; 2001 Feb; 2(2):205-6. PubMed ID: 11255888
    [No Abstract]   [Full Text] [Related]  

  • 5. Levosimendan: The current situation and new prospects.
    Moreno N; Tavares-Silva M; Lourenço AP; Oliveira-Pinto J; Henriques-Coelho T; Leite-Moreira AF
    Rev Port Cardiol; 2014 Dec; 33(12):795-800. PubMed ID: 25459636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Inotrope therapy in acute heart failure: a critical review of clinical and scientific evidence for levosimendan in the context of traditional treatment].
    Ambrosio G; Di Lenarda A; Fedele F; Gabrielli D; Metra M; Oliva F; Perna G; Senni M; De Maria R
    G Ital Cardiol (Rome); 2009 Jul; 10(7):422-33. PubMed ID: 19761100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Levosimendan--an alternative to conventional inotropic treatment of patients with acute heart failure?].
    Rasmussen T; Schmidt H
    Ugeskr Laeger; 2006 Jan; 168(3):261-5. PubMed ID: 16430807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heart failure update.
    Gomes UC; Cleland JG
    Eur J Heart Fail; 1999 Aug; 1(3):301-2. PubMed ID: 10935680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The vasoactive-inotropic score and levosimendan: time for LVIS?
    Favia I; Vitale V; Ricci Z
    J Cardiothorac Vasc Anesth; 2013 Apr; 27(2):e15-6. PubMed ID: 23507021
    [No Abstract]   [Full Text] [Related]  

  • 10. Levosimendan therapy in decompensated chronic heart failure: favourable haemodynamic and neurohormonal effects but for how long?
    Parissis JT; Farmakis D; Kremastinos DT
    Eur J Heart Fail; 2006 Mar; 8(2):215; author reply 218. PubMed ID: 16442844
    [No Abstract]   [Full Text] [Related]  

  • 11. [Levosimendan in heart failure].
    Scelsi L; Campana C; Ghio S; Monti L; Opasich C; De Feo S; Cobelli F; Orlandi M; Di Pasquale G; Tavazzi L
    Recenti Prog Med; 2004; 95(7-8):376-83. PubMed ID: 15303549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Calcium sensitizers--a new group of drugs that increase myocardium contractility].
    Laine M; Lehtonen L; Nieminen MS
    Duodecim; 2000; 116(20):2181-3. PubMed ID: 12017622
    [No Abstract]   [Full Text] [Related]  

  • 13. Levosimendan: A promising agent for the treatment of hospitalized patients with decompensated heart failure.
    Lehtonen L
    Curr Cardiol Rep; 2000 May; 2(3):233-43. PubMed ID: 10980898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In response to Leppikangas H, et al, Levosimendan as a rescue drug in experimental propranolol-induced myocardial depression: a randomized study.
    Lugassy DM; Stefan A; Dexeus D; Hoffman RS; Nelson LS
    Ann Emerg Med; 2010 May; 55(5):486; author reply 486-7. PubMed ID: 20417387
    [No Abstract]   [Full Text] [Related]  

  • 15. Levosimendan reduces plasma amino terminal proBNP in patients with decompensated heart failure.
    Mueller T; Gegenhuber A; Haltmayer M
    Int J Cardiol; 2005 Oct; 104(3):355-6; author reply 357-8. PubMed ID: 15950299
    [No Abstract]   [Full Text] [Related]  

  • 16. [Calcium mobilizers and calcium sensitizers].
    Arai M
    Nihon Rinsho; 2011 Nov; 69 Suppl 9():417-22. PubMed ID: 22724240
    [No Abstract]   [Full Text] [Related]  

  • 17. [Levosimendan for treatment of heart failure].
    Yasumura Y
    Nihon Rinsho; 2007 May; 65 Suppl 5():169-72. PubMed ID: 17571380
    [No Abstract]   [Full Text] [Related]  

  • 18. A review of levosimendan in the treatment of heart failure.
    Kasikcioglu HA; Cam N
    Vasc Health Risk Manag; 2006; 2(4):389-400. PubMed ID: 17323593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Levosimendan in heart failure after surgical repair of cardiac rupture.
    Torrado H; Ventura JL; Ruiz-Majoral A; Farrero E; Rodriguez-Castro D; Carrio ML; Miralles A
    Minerva Cardioangiol; 2009 Feb; 57(1):137-8. PubMed ID: 19202525
    [No Abstract]   [Full Text] [Related]  

  • 20. Levosimendan in two neonates with ischemic heart failure and pulmonary hypertension.
    De Carolis MP; Piastra M; Bersani I; Pardeo M; Stival E; Tempera A; Romagnoli C; Conti G; De Rosa G
    Neonatology; 2012; 101(3):201-5. PubMed ID: 22067520
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.